Guillain-Barre Syndrome (GBS) Market - By Treatment Type (First-line [IVIG, Plasma Exchange], Supportive), Type (Acute & Chronic Inflammatory Demyelinating Polyneuropathy, Miller Fisher Syndrome), Gender, Age Group, End-user – Global Forecast (2024 – 2032)

Guillain-Barre Syndrome Market Size

Guillain-Barre Syndrome Market size was valued at around USD 645.2 million in 2023 and is estimated to grow at 4.6% CAGR from 2024 to 2032, driven by an increased occurrence of the condition, especially in areas with prevalent infectious diseases.
 

A University of Minnesota study from October 2023 highlighted an increased GBS risk among COVID-19 patients, with 67% of GBS cases preceding respiratory or gastrointestinal infections. The study further observed that the average age of patients with GBS is 56, and approximately half of these patients were female. Thus, the growing incidence of disease further surges the demand for novel treatment options propelling the market growth. Furthermore, innovations in diagnostics, enhanced research and development (R&D) for novel treatments, and in immunomodulatory therapies, including intravenous immunoglobulin (IVIG) and plasma exchange (plasmapheresis), are set to further propel market expansion.
 

GBS is a rare neurological disorder characterized by the body's immune system erroneously targeting its peripheral nervous system, which consists of the nerves outside the brain and spinal cord. This immune response results in symptoms such as muscle weakness, numbness, and in some cases, paralysis. These symptoms can intensify rapidly, and the condition may become critical, especially if it impacts the muscles responsible for breathing.
 

Guillain-Barre Syndrome Market Trends

The expanding elderly demographic has been a significant driver for the growth of the GBS market, with increasing numbers of the elderly population contributing to higher demand for diagnosis, treatment, and management of the condition. According to the World Health Organization's 2021 forecast by 2030, one in six individuals worldwide will be over 60, with their numbers expected to grow from 1 billion in 2020 to 2.1 billion by 2050. The elderly population, particularly those over 80, is projected to triple to 426 million by 2050. The rise in the demographic are prone to GBS, thereby the demand for novel treatment options increases which in turn spur the market growth.
 

• A study published in the Journal of Neuroinflammation in November 2021 revealed that the risk and impact of GBS increase with age, particularly affecting more males across all age groups. This comprehensive analysis from 1990 to 2019 across 204 countries shows a clear trend that could significantly boost market growth in the forthcoming years.
   

Guillain-Barre Syndrome Market Analysis

Based on treatment type, the market is classified into first-line treatment and supportive treatment. The first-line treatment segment is expected to hold the largest market share and maintain dominance with a projected CAGR of 4.8%.
 

• The first-line treatment dominance was attributed to its widespread adoption as the primary therapeutic intervention for managing GBS.
   
• The significant market share of IVIG is anticipated, owing to the availability of diverse products such as Gamunex, Gammagard, and Privigen, alongside the expanding adoption of off-label IVIG use due to the increasing prevalence of conditions such as multifocal motor neuropathy, dermatomyositis, and others.
   
• Additionally, the substantial burden of GBS in the U.S., affecting 3,000-6,000 individuals annually according to the Centers for Disease Control and Prevention, is driving demand for effective treatments. Similarly, Assiut University's clinical trial on "Mini-pool Intravenous Immunoglobulin (MP-IVIG) in GBS," set to conclude by December 2022, is poised to introduce new products.

Based on type, the GBS market is categorized into acute inflammatory demyelinating polyneuropathy (AIDP), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), miller fisher syndrome (MFS), acute motor axonal neuropathy (AMAN), and other types. The AIDP segment is projected accounted the largest market share of 59.7% in 2023 and is expected to maintain dominance throughout the analysis period.
 

• AIDP represents the most common form of GBS, characterized by symmetrical weakness and demyelination of peripheral nerves. Its prominence in the market is attributed to its higher prevalence compared to other GBS variants. Also, as the primary type contends within clinical practice, AIDP drives demand for diagnostic tests, treatment modalities, and research initiatives in the GBS market.
   

Based on gender, the Guillain-Barre syndrome (GBS) market is bifurcated into male and female. The male segment accounted for the highest share and is expected to reach USD 678.7 million by 2032.
 

• GBS exhibited a higher prevalence in males compared to females. Factors such as genetic predispositions, hormonal influences, and environmental triggers may contribute to the higher incidence of GBS in males.
   
• Furthermore, availability of both first line treatment and supportive care along with ongoing research activities to develop innovative products will augment the market growth.
   

Based on age group, the Guillain-Barre syndrome market is classified into below 20 years, 21-40 years, 41-59 years, and 60 and above. The age segment of 41-59 years contributed the largest revenue of USD 230.6 million in 2023.
 

• The 41-59 years age group represented a significant portion of GBS cases, possibly due to a combination of factors such as increased susceptibility to infections, higher prevalence of autoimmune conditions, and age-related changes in the immune system. Targeting this age demographic is crucial for market stakeholders in developing tailored diagnostic and treatment solutions.
   

Based on end-user, the guillain-barre syndrome market is categorized into hospitals, clinics, rehabilitation centers, and other end-users. The hospital segment is projected to reach USD 401.4 million growing at a CAGR of 4.6% during the analysis period.
 

• This surge in demand can be attributed to hospitals being primary centers for GBS diagnosis, treatment, and management. With specialized medical professionals, advanced diagnostic facilities, and comprehensive care infrastructure, hospitals are pivotal in providing acute care, rehabilitation services, and long-term support to GBS patients. Such benefits associated with hospital setting will supplement the market growth.

U.S. dominated the North American Guillain-Barre syndrome market accounting for the highest market revenue of USD 305.4 million in 2023 anticipating significant growth over the analysis period.
 

• This dominance stems from various factors, including a growing geriatric population at higher risk of GBS, the presence of major market players, and increased awareness about GBS. According to the Centers for Disease Control and Prevention (CDC), Campylobacter jejuni infection, a common cause of GBS, particularly affects individuals over 50. Therefore, prioritizing early diagnosis and comprehensive treatment, including immunotherapy and rehabilitation services, the country fosters a supportive environment for U.S. patients anticipating the market expansion.
   
• Also, public funding for GBS-related projects, exemplified by the National Institute of Neurological Disorders and Stroke's (NINDS) funding approval for a research project, further augments regional market growth.
   

Germany exhibited a high growth potential in the European Guillain-Barre syndrome market.
 

• Rising focus on innovation and research, country aims to expedite the clinical trials and collaborates with pharmaceutical companies to develop new therapies and treatment protocols for GBS are few factors driving the market demand.
   
• In addition, the country’s robust network of hospitals and specialized neurological centers ensuring prompt diagnosis, multidisciplinary treatment, and rehabilitation services for individuals with GBS anticipates attracting a large patient.
   
• Further, collaborations among academic institutions, healthcare providers, and pharmaceutical firms stimulate innovation and therapeutic progress in the GBS therapeutic area, thereby propelling market expansion.
   

Japan gained traction in the GBS market anticipating substantial growth during the analysis period.
 

• Robust clinical research and partnerships with global companies to extend insights into GBS pathophysiology and treatment alternatives indicate significant growth prospects in the foreseeable future. Also, regulatory bodies in Japan scrutinize and authorize new GBS therapies, guaranteeing adherence to safety and efficacy criteria for patient welfare. This enables a positive awareness among the patient population which will in turn spur the country level market growth.
   
• Further, in Japan, rehabilitation services like physical and occupational therapy play a vital role in enhancing functional capabilities as part of managing GBS, thus contributing to the forecasted expansion of the market.
   

Guillain-Barre Syndrome Market Share

The key players within the competitive landscape prioritize vying for product effectiveness, safety credentials, pricing tactics, and geographical reach. Primary areas of concentration involve R&D, strategic partnerships, and initiatives for market expansion. These endeavours aimed to secure a competitive advantage and bolster market share.
 

Guillain-Barre Syndrome Market Companies

Some of the prominent market players operating in the GBS industry include:

• AbbVie Inc.
• Biogen Inc.
• Cadila Healthcare Limited
• CSL Behring LLC
• F. Hoffmann-La Roche Ltd.
• GSK plc
• Grifols SA
• LGM Pharmaceuticals Inc.
• Merck & Co. Inc.
• Octapharma AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
   

Guillain-Barre Syndrome Industry News:

• In October 2023, Annexon Inc announced that the European Medicine Agency (EMA) granted orphan drug designation to ANX005 for the treatment of Guillian-Bare Syndrome. This strategy is expected to enhance their outreach to untapped economies.
   
• In April 2023, Hansa Biopharma initiated enrollment for a Phase II trial investigating imlifidase in GBS. This trial aims to assess the safety, tolerability, and efficacy of imlifidase alongside the standard IVIG treatment for GBS patients. These research endeavors are poised to expedite company product offering in the GBS therapeutic landscape.
   

The Guillain-Barre syndrome market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• First-line treatment
  • Intravenous immunoglobulin (IVIG)
  • Plasma exchange (Plasmapheresis) 
• Supportive treatment

Market, By Type

• Acute inflammatory demyelinating polyneuropathy (AIDP)
• Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
• Miller fisher syndrome (MFS)
• Acute motor axonal neuropathy (AMAN)
• Other types

Market, By Gender

• Male
• Female

Market, By Age Group

• below 20 years
• 21-40 years
• 41-59 years
• 60 and above

Market, End-user

• Hospitals
• Clinics
• Rehabilitation centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa